title: What happens after conversion of treatment to continuous ambulatory peritoneal dialysis from hemodialysis?
abstract: A prospective study was planned to follow the clinical and laboratory data of hemodialysis (HD) patients after change of treatment to continuous ambulatory peritoneal dialysis (CAPD). Patients who had been on the HD program for more than 6 months were selected and followed for at least 6 months under CAPD treatment. Measured parameters included hemoglobin, ferritin, C-reactive protein (CRP), calcium, phosphorus, and intact parathyroid hormone (iPTH) levels; lipid profile; total protein and albumin; body mass index and triceps skin fold thickness; echocardiographic findings; and medications administered. We followed 34 patients (12 males, 22 females; mean age: 43.5 +/- 14.5 years; mean HD duration: 36.6 +/- 24.76 months) for a mean period of 19.8 +/- 11.9 months after change of treatment to CAPD. We saw a significant increase in mean hemoglobin, cholesterol, triglyceride, high-density lipoprotein (HDL), lipoprotein (a) [Lp(a)], phosphorus, and iPTH levels. We observed a decrease in erythropoietin dose, mean ferritin levels, systolic blood pressure (139.4 +/- 22.8 mmHg vs 114.4 +/- 21.0 mmHg, p = 0.001), diastolic blood pressure (85.7 +/- 12.6 mmHg vs 73.5 +/- 17.6 mmHg, p = 0.002), percentage of left ventricular hypertrophy, systolic and diastolic dysfunction, and the number of hypertensive drugs received. A significant improvement in the nutritional status of the patients (total protein, body mass index and triceps skin fold thickness) was also seen. In conclusion, CAPD treatment has a short-term outcome superior to that of HD in terms of better nutritional status and better control of hypertension and anemia.
authors.affiliation: Department of Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Sezer
authors.forename: N
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Z
authors.initials: Z
authors.lastname: Arat
authors.forename: G
authors.initials: G
authors.lastname: Güz
authors.forename: S
authors.initials: S
authors.lastname: Sengül
authors.forename: B
authors.initials: B
authors.lastname: Akman
authors.forename: A
authors.initials: A
authors.lastname: Haberal
authors.forename: M
authors.initials: M
authors.lastname: Turan
authors.forename: M
authors.initials: M
authors.lastname: Haberal
mesh_terms: D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D001798:Blood Proteins / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002118:Calcium / Q000097:blood; D005260:Female; D005293:Ferritins / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008055:Lipids / Q000097:blood; D008297:Male; D009752:Nutritional Status; D010281:Parathyroid Hormone / Q000097:blood; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010758:Phosphorus / Q000097:blood; D011446:Prospective Studies; D006435:Renal Dialysis
chemical_list: D001798:Blood Proteins; D006454:Hemoglobins; D008055:Lipids; D010281:Parathyroid Hormone; D010758:Phosphorus; D002097:C-Reactive Protein; D005293:Ferritins; D002118:Calcium